What is LINEA System?
LINEA System operates at the intersection of clinical research and digital transformation. Its flagship platform, AcceleTrial, serves as a sophisticated Study Start-up Management System (SSMS) designed to mitigate the inefficiencies inherent in traditional clinical trial initiation. By utilizing a proprietary network of over 300,000 global investigators, the company provides sponsors and clinical research organizations (CROs) with data-driven site identification and engagement capabilities. This technological approach significantly reduces the time-to-market for new therapies, positioning LINEA System as a critical partner for top-tier pharmaceutical entities seeking to optimize patient enrollment and site selection processes.
How much funding has LINEA System raised?
LINEA System has raised a total of $64K across 1 funding round:
Debt
$64K
Debt (2021): $64K with participation from PPP
Key Investors in LINEA System
PPP
Public-Private Partnership
What's next for LINEA System?
With the recent infusion of capital, LINEA System is expected to accelerate its product development roadmap and expand its footprint within the global life sciences ecosystem. The strategic focus will likely center on enhancing the predictive analytics capabilities of the AcceleTrial platform to further streamline site activation timelines. As the clinical trial landscape becomes increasingly complex, the company's ability to provide scalable, technology-enabled solutions will be paramount in maintaining its competitive advantage. Future growth initiatives will likely involve deepening integration with existing CRO workflows and expanding the reach of its investigator network to support more diverse and complex therapeutic trials.
See full LINEA System company page
